- Merck dosed the first patient in a Phase III study of oral cladribine for generalized Myasthenia Gravis (gMG), a rare autoimmune disorder causing muscle weakness.
August 29 2024 12:43:51 UTC– Merck announced the start of Phase III study for Oral Cladribine in gMG, a rare neuromuscular disorder causing muscle weakness.
This study evaluates the efficacy and safety of cladribine capsules, potentially the first oral treatment for gMG. Cladribine targets B and T lymphocytes, aiming to reduce disease progression and treatment burden.
Cladribine capsules could be the first oral treatment for gMG, targeting disease progression by addressing the root cause. The study aims to evaluate efficacy and safety in 240 patients.